{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhalation+powder&page=3",
    "query": {
      "intervention": "Placebo inhalation powder",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 204,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhalation+powder&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhalation+powder&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T20:23:39.170Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02786927",
      "title": "Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo ELLIPTA device",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules for use in HANDIHALER device",
          "type": "DRUG"
        },
        {
          "name": "Inhaler Preference Questionnaire Version 1",
          "type": "OTHER"
        },
        {
          "name": "Inhaler Preference Questionnaire Version 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2016-06-21",
      "completion_date": "2016-10-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 22,
      "location_summary": "Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786927"
    },
    {
      "nct_id": "NCT02178540",
      "title": "Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tobi Podhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-08",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-05-23",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178540"
    },
    {
      "nct_id": "NCT01706328",
      "title": "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/VI 100/25 Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 828,
      "start_date": "2012-10-15",
      "completion_date": "2013-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 16,
      "location_summary": "Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Woodbury",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01706328"
    },
    {
      "nct_id": "NCT03611699",
      "title": "Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Umeclidinium / Vilanterol Dry Powder Inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gary L. Pierce",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2019-01-24",
      "completion_date": "2020-04-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611699"
    },
    {
      "nct_id": "NCT02633007",
      "title": "A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "CVT-301 (levodopa inhalation powder)",
          "type": "DRUG"
        },
        {
          "name": "Carbidopa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2015-12",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633007"
    },
    {
      "nct_id": "NCT03394989",
      "title": "BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchial Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone propionate/salmeterol 100/50 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cipla Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1366,
      "start_date": "2018-10-17",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-08-13",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03394989"
    },
    {
      "nct_id": "NCT05161156",
      "title": "Bioequivalence Study of Tiotropium Bromide Inhalation Powder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Test Product (tiotropium bromide inhalation powder)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "18 mcg of Spiriva (Reference Product)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Phargentis SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2022-03-24",
      "completion_date": "2022-11-29",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 3,
      "location_summary": "Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina",
      "locations": [
        {
          "city": "Anderson",
          "state": "South Carolina"
        },
        {
          "city": "Gaffney",
          "state": "South Carolina"
        },
        {
          "city": "Union",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161156"
    },
    {
      "nct_id": "NCT07344558",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [
        {
          "name": "MNKD-201(Nintedanib DPI)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-12-22",
      "completion_date": "2026-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 9,
      "location_summary": "Fresno, California • Palm Springs, California • Doral, Florida + 5 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07344558"
    },
    {
      "nct_id": "NCT05798923",
      "title": "LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension Due to Lung Diseases and Hypoxia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LAM-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IRulya Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 85,
      "start_date": "2023-08-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05798923"
    },
    {
      "nct_id": "NCT02260492",
      "title": "Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "OT329 (combination of fluticasone propionate and salmeterol xinafoate)",
          "type": "DRUG"
        },
        {
          "name": "Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oriel Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 879,
      "start_date": "2014-09",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-15",
      "last_synced_at": "2026-10-08T20:23:39.170Z",
      "location_count": 47,
      "location_summary": "Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02260492"
    }
  ]
}